The off label issue surfaces often in drug-and-device litigation, even where it should remain wholly submerged. Plaintiffs view off-label promotion as a way of altering the risk-benefit calculation, undermining preemption, and, of course, parading "bad conduct" in front of the jury.
FULL ARTICLE AT Drug and Device Law